Open AccessCardiovascular risk in type 2 diabetes patients
Author(s) -
О Д Остроумова,
Голобородова Ирина Васильевна,
В. М. Фомина
Publication year - 2018
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2018-4-81-94
Subject(s) - medicine , dapagliflozin , type 2 diabetes , diabetes mellitus , context (archaeology) , obesity , intensive care medicine , endocrinology , paleontology , biology
Cardiovascular diseases remain leading cause of high mortality in diabetes patients. The article is focused on the influence of diabetes on cardiovascular risks. The prevalence presented, as the significance of the main and additional risk factors of cardiovascular diseases in the development of macrovascular complications in diabetes. In the context of influence on cardiovascular risks, modern glucose lowering drugs are considered, the safety and efficacy properties. Advantages of dapagliflozin underscored, the novel oral drug of new generation, with safe and prominent antidiabetic effect and ability to correct the main factors of cardiovascular risk (obesity, hypertension).